BioVaxys MVP-S Survivin Peptide Vaccine PESCO Phase 1B/2 Trial Accepted at ASCO 2026 in Recurrent Ovarian Cancer
BioVaxys announced April 27 that the abstract from the investigator-initiated PESCO trial — an open-label, non-randomized Phase 1B/2 study evaluating the company's MVP-S (maveropepimut-S) DPX-formulated peptide vaccine in combination with pembrolizumab and cyclophosphamide in recurrent epithelial ovarian cancer — has been accepted for presentation at the 2026 ASCO Annual Meeting in Chicago (May 29–June 6). MVP-S is a five-peptide survivin-targeted formulation that pairs the peptides with a T-helper sequence and an innate-immune stimulant; the program tests whether the cytotoxic T-cell response can be combined effectively with checkpoint blockade in platinum-resistant disease.